PPARA and metabolic dysfunction-associated steatohepatitis: The PPAR pan agonist lanifibranor (IVA-337) and the PPARα/γ dual agonist saroglitazar are currently in clinical trials for NASH (phase 3 in NCT04849728 and 2b in NCT05011305, respectively).